Co-Authors
This is a "connection" page, showing publications co-authored by Christian Devaux and Didier Raoult.
Connection Strength
7.242
-
New Insights Into the Physiopathology of COVID-19: SARS-CoV-2-Associated Gastrointestinal Illness. Front Med (Lausanne). 2021; 8:640073.
Score: 0.930
-
Can ACE2 Receptor Polymorphism Predict Species Susceptibility to SARS-CoV-2? Front Public Health. 2020; 8:608765.
Score: 0.929
-
Can hydroxychloroquine be protective against COVID-19-associated thrombotic events ? J Microbiol Immunol Infect. 2021 Feb; 54(1):37-45.
Score: 0.922
-
ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome. J Microbiol Immunol Infect. 2020 Jun; 53(3):425-435.
Score: 0.881
-
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020 May; 55(5):105938.
Score: 0.871
-
The Microbiological Memory, an Epigenetic Regulator Governing the Balance Between Good Health and Metabolic Disorders. Front Microbiol. 2018; 9:1379.
Score: 0.774
-
A Possible Role of Remdesivir and Plasma Therapy in the Selective Sweep and Emergence of New SARS-CoV-2 Variants. J Clin Med. 2021 Jul 24; 10(15).
Score: 0.240
-
Expression of ACE2, Soluble ACE2, Angiotensin I, Angiotensin II and Angiotensin-(1-7) Is Modulated in COVID-19 Patients. Front Immunol. 2021; 12:625732.
Score: 0.238
-
Spreading of a new SARS-CoV-2 N501Y spike variant in a new lineage. Clin Microbiol Infect. 2021 Sep; 27(9):1352.e1-1352.e5.
Score: 0.236
-
Current Status of Putative Animal Sources of SARS-CoV-2 Infection in Humans: Wildlife, Domestic Animals and Pets. Microorganisms. 2021 Apr 17; 9(4).
Score: 0.235
-
Mink, SARS-CoV-2, and the Human-Animal Interface. Front Microbiol. 2021; 12:663815.
Score: 0.234
-
Emergence and outcomes of the SARS-CoV-2 'Marseille-4' variant. Int J Infect Dis. 2021 May; 106:228-236.
Score: 0.234
-
COVID-19 re-infection. Eur J Clin Invest. 2021 May; 51(5):e13537.
Score: 0.234
-
Natural history of COVID-19 and therapeutic options. Expert Rev Clin Immunol. 2020 12; 16(12):1159-1184.
Score: 0.230
-
Teicoplanin: an alternative drug for the treatment of COVID-19? Int J Antimicrob Agents. 2020 Apr; 55(4):105944.
Score: 0.054